NeoPhore Limited, a small molecule cancer immuno-oncology company, has announced the appointment of Dr Matthew Baker as vice president of immunology to the company’s management team.
Dr Baker has more than 15 years’ experience developing biologics in biotech and pharma companies and is a research expert in B and T cell immunology, including drug immunogenicity. He has held entrepreneurial and leadership positions across the biotechnology industry including chief scientific officer of Abzena plc and co-founder, chief scientific officer of Denceptor Therapeutics.
Commenting on the appointment Jeff Roix, CEO of NeoPhore, said: “I’m very pleased to welcome Matthew to the NeoPhore management team. His broad immunology and immune therapeutics development expertise will be invaluable as we progress our discovery programmes towards the clinic.
“NeoPhore is now in a strong position to accelerate the development of its highly promising first-in-class I/O drug strategy targeting DNA mismatch repair (MMR), and we look forward to Matthew’s leadership as we develop our new MMR product concept in the future.”